. 2016 Sep 7;22(33):7579–7586. doi: 10.3748/wjg.v22.i33.7579

Table 7.

Comparison of autoantibodies between typed drug-induced liver injury and primary biliary cirrhosis patients n (%)

	Autoantibodies	ANA	AMA	SMA	AMA-M2	AMA-M4	AMA-M9
Hepatocellular type DILI (n = 90)	43 (47.7)^a	41 (45.5)^a	2 (2.22)^a	2 (2.22)	2 (2.22)^a	0^a	1 (1.11)^a
Cholestatic type DILI (n = 20)	10 (50.0)^a	8 (40.0)^a	2 (10.0)^a	1 (5.00)	1 (5.00)^a	0^a	1 (5.00)
Mixed type DILI (n = 14)	6 (42.8)^a	6 (42.8)^a	0^a	1 (7.14)	0^a	1 (7.14)	1 (7.14)
PBC (n = 116)	106 (91.3)	98 (84.4)	98 (84.4)	2 (1.72)	98 (84.4)	34 (29.3)	19 (16.3)

P < 0.05 vs the PBC group. DILI: Drug-induced liver injury; PBC: Primary biliary cirrhosis; ANA: Antinuclear antibody; AMA: Antimitochondrial antibody; SMA: Anti-smooth muscle antibody.